| Stage | A | % of rev | BIO | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $1.9B | 100.00% | $651M | 100.00% | A ×2.88 |
| Gross profit | $1.0B | 55.48% | $346M | 53.12% | A +2.4pp |
| Operating income | $444M | 23.64% | $73M | 11.15% | A +12.5pp |
| Pre-tax income | $444M | 23.64% | $542M | 83.27% | BIO +59.6pp |
| Net income | $362M | 19.28% | $371M | 57.05% | BIO +37.8pp |
| Stage | A | BIO | Gap · A − B |
|---|---|---|---|
| Revenue | $1.9B100.00% | $651M100.00% | A ×2.88 |
| Gross profit | 55.48%$1.0B | 53.12%$346M | A +2.4pp |
| Operating income | 23.64%$444M | 11.15%$73M | A +12.5pp |
| Pre-tax income | 23.64%$444M | 83.27%$542M | BIO +59.6pp |
| Net income |
| 19.28%$362M |
| 57.05%$371M |
| BIO +37.8pp |